“Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer’s disease has a host of unexpected anti-aging effects in animals.The Salk team expanded upon their previous development of a drug candidate, called J147, which takes a different tack by targeting Alzheimer’s major risk factor—old age. In the new work, the team showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer’s research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features, as detailed November 12, 2015 in the journal Aging.”
A national team of researchers has developed a first-of-its-kind, 3D-printed guide that helps regrow both the sensory and motor functions of complex nerves after injury. The groundbreaking research has the potential to help more than 200,000 people annually who experience nerve injuries or disease.
Read more here.
This is rather exciting news. If it works in humans, it would be a game changer. A number of media sites wrote about this work by Dr Panos Anastasiadis and his team at the Mayo Clinic. Here’s the BBC’s story.
“Scientists believe they may have found a way to turn cancerous cells back into healthy tissue.
Their lab-based work suggests there is a biological step that can restore normality and stop cells replicating out of control.”
Here’s an informative article by David Ewing Duncan on gut bacteria and the brain.
According to Nature, researchers are poised to meet with the FDA this month to discuss “medicines that delay ageing-related disease as legitimate drugs.” This makes sense, given that there are a number of scientific teams working on such compounds. Nir Barzilai of the Albert Einstein College of Medicine in New York is one of those scientists, and the compond he’s focused on is metformin, which has shown promise in previous studies.
A huge advance. Here’s the story from Discover Mag:
“A team of regenerative scientists and surgeons at Massachusetts General Hospital successfully grew a semi-functional rat forelimb in the lab, employing a technique previously used to build bio-artificial organs. If someday perfected, the experimental approach could be used to create human limbs suitable for transplantation.”
From the WSJ:
“A Food and Drug Administration advisory panel has recommended the first drug to help combat female sexual dysfunction. And Sprout Pharmaceuticals, which owns the pill, hopes agency approval will occur in mid-August.”
Here’s the description:
“A one-day event with leading influencers and visionaries to reimagine the American dream in an intimate setting at The Battery in San Francisco. NOVUS is a tour de force that unites global shapers from around the world to tackle the today’s grand challenges via actionable change. “
From Business Insider:
“It can take weeks to identify drugs targeting cancer-causing mutations. Watson can do it in minutes and has in its database the findings of scientific papers and clinical trials on particular cancers and potential therapies.”
From the LAT:
“So far, the medical implant has been tested in three children between the ages of 3 months and 16 months. Before getting the implant, the young patients had spent much of their lives in intensive care, where they needed to be on ventilators full-time to help them breathe. But after surgeons inserted the small white device around their narrow airways, all three recovered rapidly, according to a study published this week in the journal Science Translational Medicine.”
Scientists controlled a mouse’s behavior using a method called “DREADDs (designer receptors exclusively activated by designer drugs).” Not a great acronym (given the potential abuse for such a method), but it does reflect a shift away from linking mental “illnesses to “chemical imbalances” in the brain, instead tracing them to miswiring and misfiring in neuronal circuits.” Here’s the story.
“What do you do when a patient needs a blood transfusion but you don’t have their blood type in the blood bank? It’s a problem that scientists have been trying to solve for years but haven’t been able to find an economic solution – until now.
University of British Columbia chemists and scientists in the Centre for Blood Research have created an enzyme that could potentially solve this problem. The enzyme works by snipping off the sugars, also known as antigens, found in Type A and Type B blood, making it more like Type O. Type O blood is known as the universal donor and can be given to patients of all blood types.”
Read more at: http://phys.org/news/2015-04-donated-blood-universal.html#jCp
Here’s the latest news piece to cite 100 Plus. The author interviewed some naysayers on the topic of healthspan, but ultimately I think it’s clear that if Silicon Valley can figure out how to increase human health, that is a good thing for everyone.
Researchers at Duke University have engineered a polio virus to infect cancer cells. This weakens the cancer and alerts the body’s immune system to the fact that there is something growing in the body that shouldn’t be there. It’s brilliant work and 60 Minutes has done a great job of capturing the story. Watch it here.
Here’s the story from Forbes.
“The company has hired Richard Scheller, who led drug discovery at biotech icon Genentech for 14 years before announcing he would retire in December, and who has won some of science’s top awards, including the Lasker Prize, often referred to as “America’s Nobel,” and the Kavli Prize.”